

Cite this: *RSC Adv.*, 2019, 9, 37300

MicroRNAs and long noncoding RNAs: new regulators in cell fate determination of mesenchymal stem cells

Zixiang Wu, ^{abc} Shujing Liang, ^{abc} Wenyu Kuai,^{abc} Lifang Hu ^{*abc} and Airong Qian^{*abc}

Mesenchymal stem cells (MSCs) are multipotent cells that are able to differentiate into numerous cell types, including well-known inherent osteoblasts, adipocytes, and chondrocytes, and other cell types, such as hepatocytes, cardiomyocytes and nerve cells. They have become a favorite source of cell-based therapy. Therefore, knowing the mechanism that determines the cell fate of MSCs is important not only for deep understanding of the MSC function but also for the manipulation of MSCs for clinical application. Recently, studies have demonstrated that microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), the two best studied noncoding RNAs, show key roles in cell fate determination of MSCs by functioning as vital regulators of their target gene expression or signaling transduction. Here, we summarize the characteristics of miRNAs and lncRNAs, and review the recent advances proving their profound involvement in determining the cell fate of MSCs to inherent osteoblast, adipocyte, and chondrocyte cells, and to several key cell types including hepatocytes, cardiomyocytes and nerve cells. This will provide researchers with a deep understanding of the role of miRNAs and lncRNAs in MSCs and provide guidance for future research.

Received 21st August 2019
Accepted 30th October 2019

DOI: 10.1039/c9ra06563f

rsc.li/rsc-advances

1 Introduction

Mesenchymal stem cells (MSCs), with strong self-renewal ability and plasticity, have the potential to differentiate into multiple

cell types, including well-known inherent osteoblasts, adipocytes, and chondrocytes, and other cell types such as hepatocytes, cardiomyocytes and nerve cells.¹ Possessing multipotency, MSCs have been the favorite source of cell therapy and stem cell therapy and have attracted more and more researcher attention for treating various diseases, such as repairing ischemic heart, bone, and skeletal muscle.^{2–4} Therefore, uncovering the mechanism that regulates MSC differentiation or cell fate determination is essential for both understanding MSC function and their clinical application.

MiRNAs and lncRNAs are two kinds of noncoding RNA, which are transcribed from DNA but do not encode proteins.⁵ MiRNAs

^aLaboratory for Bone Metabolism, Key Laboratory for Space Biosciences and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an 710072, China. E-mail: wuzx@mail.nwpu.edu.cn; liangsj@mail.nwpu.edu.cn; kuaiwenyu@mail.nwpu.edu.cn; hulifang@nwpu.edu.cn; qianair@nwpu.edu.cn

^bResearch Center for Special Medicine and Health Systems Engineering, School of Life Sciences, Northwestern Polytechnical University, Xi'an 710072, China

^cNPU-UAB Joint Laboratory for Bone Metabolism, School of Life Sciences, Northwestern Polytechnical University, Xi'an 710072, China



Zixiang Wu, born in 1991, a PhD candidate majoring in aerospace medicine and studying in Laboratory for Bone Metabolism, School of Life Sciences, Northwestern Polytechnical University. Focus on the microgravity-induced bone loss and osteoporosis research, and MSC differentiation.



Shujing Liang, born in 1995, a master student studying cell biology in Laboratory for Bone Metabolism, School of Life Sciences, Northwestern Polytechnical University. Focus on the research of osteoporosis and osteoblast proliferation and differentiation.



and lncRNAs are not junk sequence but emerge as powerful regulators of gene expression. They are best studied and have been shown to play critical roles in diverse cellular processes, including cell proliferation, cell differentiation and apoptosis.^{6,7} Recently, miRNAs and lncRNAs have been demonstrated to play important regulatory roles in determining cell fate of MSCs.

In this review, we discuss characteristics of miRNAs and lncRNAs and review recent advances proving their profound involvement in determining cell fate of MSCs to inherent osteoblast, adipocyte, and chondrocyte, and to several key cell types including hepatocyte, cardiomyocyte and nerve cell. This review will provide researchers deep understanding of the role of miRNAs and lncRNAs in MSCs, and provide novel targets for disease treatment.

2 MicroRNAs (miRNAs)

2.1 Characteristics of miRNAs

MiRNAs are noncoding, ~22 nucleotides single-stranded RNAs that are involved in the regulation of gene expression to coordinate multiple biological processes.^{8,9} They are ubiquitous, ranging from virus¹⁰ to human tissues¹¹ and emerge as key post-transcriptional regulators of gene expression by suppressing target messenger RNAs (mRNAs) translation efficiency or degrading target mRNAs.^{12,13}



Wenyu Kuai, born in 1998, a junior undergraduate student studying biotechnology at School of Life Sciences, Northwestern Polytechnical University. Participate in the research of MSC differentiation.



Lifang Hu, born in 1983, PhD, an Assistant Professor working in Laboratory for Bone Metabolism, School of Life Sciences, Northwestern Polytechnical University. Focus on bone metabolic diseases research, including senile osteoporosis and microgravity-induced bone loss. Review Editor of *Frontiers in Physiology* and Guest Reviewer of *Experimental Biology and Medicine*.

MiRNAs are ubiquitous in animal genomes and they are mainly derived from the introns of the pre-mRNA or the genetic interval of the genome through transcription.¹⁴ Mature miRNAs are generated through a series of processes (Fig. 1). Firstly, the primary miRNA (pri-miRNA) with hundreds of nucleotides, which contains mature miRNA sequences, is first transcribed from the introns or the genetic interval of DNA by RNA polymerase II in the nucleus.¹⁵ Following, the pri-miRNA is trimmed twice by the RNase III Drosha with the double-stranded RNA binding protein DiGeorge Syndrome Critical Region 8 (DGCR8) to produce precursor miRNA (pre-miRNA) with approximately 60 to 100 nucleotides coil.¹⁶ Then, the pre-miRNA is exported from the nucleus to the cytoplasm by Ran-GTP dependent exportin-5 and is cleaved into mature miRNA by RNase III endonuclease enzyme Dicer. Finally, in the cytoplasm, mature miRNA is assembled into RNA-Induced Silencing Complex (RISC) with the interaction of TAR RNA-binding protein (TRBP) and Argonaute 2 (Ago 2) to target the 3' untranslated regions (3' UTR) of its target mRNA.¹⁷

2.2 Action mode of miRNAs

By interacting with target mRNA, miRNA regulates gene expression and induces functional changes. Generally, miRNAs inhibit the translation process of its target mRNA by binding to the 3' terminal UTR of the target mRNA. The 5' end of miRNA is known as a seed region and miRNA targets the 3' UTR of mRNA by complementary base pairing to mediate post-transcriptional gene silencing¹⁸ (Fig. 1). According to the base pairing degree, mRNA is either degraded or inhibited by miRNAs.¹⁹ Besides, studies have shown that miRNAs can also bind to the promoter, coding region and 5' UTR²⁰ (Fig. 1).

3 Long non-coding RNAs (lncRNAs)

3.1 Characteristics of lncRNAs

lncRNAs, which are distinguished from small RNA with more than 200 nucleotides, are another class of noncoding RNA.²¹ Rather than the "noise" considered previously, lncRNAs are critical regulators involved in almost a variety of biological processes, including X chromosome silencing, epigenetic and



Aorong Qian, born in 1972, PhD. Professor working in Laboratory for Bone Metabolism, School of Life Sciences, Northwestern Polytechnical University. Focus on bone metabolic diseases research, including osteoporosis and osteoarthritis. Associate Editor of *Frontiers in Physiology* and a member of the editorial board of *Endocrine, Metabolic & Immune Disorders – Drug Targets* magazine.






Fig. 1 Schematic program of biogenesis of miRNA and its action mode.

transcriptional activation, transcriptional interference and nuclear trafficking.²² They are divided into 5 main types depending on the position and orientation of the transcription site relative to adjacent gene.^{23,24} (1) Sense lncRNAs. The transcription direction of this type lncRNA is the same as the direction of transcription of its adjacent mRNA. (2) Antisense lncRNAs. They are endogenous RNAs of organisms and are often located at both ends of protein-coding genes. (3) Intergenic lncRNAs. They are discrete transcription units that intervene in protein-coding loci. (4) Intronic lncRNAs transcript completely derived from introns of protein-coding genes. (5) Bidirectional lncRNAs. The lncRNAs can be simultaneously transcribed from the same and opposite directions as the adjacent mRNA.

lncRNA can be derived from promoters, enhancers, and intergenic regions with eukaryotic RNA processing.²⁵ lncRNAs are generally produced through transcription mediated by RNA polymerase II and the transcriptional activators such as switching defective/sucrose non-fermenting (SWI/SNF).²⁶ After transcription, lncRNAs are mostly spliced, capped and polyadenylated in a similar way as mRNA.^{25,27}

3.2 Action mode of lncRNAs

By binding to protein partners, lncRNAs possess regulatory capacities. Although there are still limited knowledge of lncRNAs, studies have demonstrated several main action modes of lncRNAs, acting as molecular signal, decoy, guide, scaffold, and enhancer (Fig. 2).²⁸ (1) Molecular signal: under different stimulation conditions and signaling pathways, lncRNAs are specifically transcribed and serve as signal molecules in the transmission of specific signaling

pathways.²⁹ Some lncRNAs possess regulatory functions while others are merely by-products of transcription.²⁷ (2) Decoy: the action mode of lncRNA is molecular sink during cellular processes.⁷ After lncRNAs transcribed, they will bind to transcription factors directly and the function of such transcription factors is blocked, thereby regulating downstream gene transcription.³⁰ In short, signals and decoys control the activation or suppression of gene.³¹ (3) Guides: lncRNAs can serve as a guide that recruits protein complex and nuclear proteins to chromatin sites to regulate downstream gene expression. Evidences demonstrate that lncRNAs can guide changes in gene expression either in *cis* (on neighboring genes) or in *trans* (distantly located genes). lncRNAs such as air and eRNAs (enhancer RNAs) play a role in *cis* by diffusing from transcriptionally controlled focus sequence elements such as enhancers or promoters, while lncRNAs such as HOTAIR and lincRNA-p21 function in *trans* requiring some interacting partners to be properly localized to the action sites.²⁷ (4) Scaffold: as a “central scaffold”, scaffolds can bring multiple related transcription factors that can be bound to this lncRNA, and they can form lncRNA-ribonucleoprotein (RNPs) complexes. This form can realize the intersection and integration of information between different signal paths, which is beneficial for the body/cell to quickly feedback and adjust external signals,^{27,32} such as HOTAIR,³³ 7SL.³⁴ (5) Enhancers: some lncRNAs act as enhancers to participate in the regulation of genes, and stabilize the chromatin loop.³⁵ In addition, it can enhance the inflammatory response with a number of ways, such as increasing the transcription of pro-inflammatory cytokines by enhancing inflammatory signals, such as NF- κ B signaling.³⁶






Fig. 2 The classification (a) and action modes (b) of lncRNAs.

4 MiRNAs and cell fate determination of MSCs

MSCs are multipotent stem cells with the capability of self-renewing and differentiating into multiple cell lineages, including osteoblasts, adipocytes and chondrocytes.³⁷ Functioning as critical regulators, numerous miRNAs have been demonstrated to play important roles in regulating the differentiation of MSCs.^{38,39}

4.1 MiRNAs and osteogenic differentiation of MSCs

Evidences have shown that miRNAs regulate the osteogenic differentiation of MSCs and multiple signaling pathways are involved in, such as Wnt signaling,⁴⁰ BMP signaling,^{41,42} and Notch signaling.⁴³ Wnt/ β -catenin signaling pathway plays a critical role in cell fate determination of MSCs. Wnt ligands function by interacting 7-transmembrane domain-spanning frizzled (FZD) receptor and LRP5/6 coreceptors, thereby stabilizing β -catenin by preventing it from phosphorylation and degradation, which facilitates β -catenin translocate into the nucleus to regulate various target genes expression. Wnt/ β -catenin signaling pathway has become a prominent channel during miRNA-mediated osteogenic differentiation of MSCs.⁴⁴ Wang *et al.* found that increased miR-346 significantly promoted osteogenic differentiation of hMSCs by inhibiting the expression of glycogen synthase kinase-3 (GSK-3 β).⁴⁵ MiR-346 directly bound to the 3'-UTR of GSK-3 β mRNA, which resulted in decreased level of GSK-3 β , and increased osteogenic differentiation.⁴⁵ Recent studies reveal that miRNAs also regulate osteogenic differentiation and bone formation through bone

morphogenetic proteins (BMP)/Smads signaling pathway. In fact, BMPs are potent inducers of osteoblastogenesis during bone development.⁴⁶ They undergo site-specific phosphorylation and activate Smad-1, Smad-5 and Smad-8, which are transcription factors and enter into the nucleus to regulate the expression of runt related transcription factor 2 (Runx2), osterix (OSX), osteocalcin (OCN) and osteopontin (OPN) to regulate osteoblast differentiation.⁴⁷ Liu *et al.* have reported that miR-155 inhibits osteogenic differentiation induced by BMP9 both in mMSCs and hMSCs with reduced expression of osteogenesis-related genes.⁴⁸ TGF- β acts as another important signaling pathway that inhibits osteoblast differentiation and works with BMP2 to form a TGF- β /BMP signaling pathway. Bhushan *et al.* have found that miR-181a binds directly to Rgs4 and Gata6 and promotes osteoblast differentiation by repressing the TGF- β signaling pathway.⁴⁹ Besides, miR-21 promotes BMP9-induced osteogenic differentiation of MSCs by inhibiting the BMP/Smads signaling pathway under the interaction of Smad7.⁵⁰ These findings suggest that different miRNAs play different roles in regulating MSCs differentiation. The difference may be due to the different targets of different miRNAs. Moreover, the role of miRNAs in osteogenic differentiation through the Notch signaling pathway is receiving increasing attention.⁵¹ MiR-34a inhibits hMSCs differentiation by siRNA-mediated reduction of the expression of Jagged1 (JAG1), a ligand of the Notch1 signaling pathway. The inhibition of miR-34a becomes a potential new therapeutic strategy for enhancing bone formation.⁵² The overexpression of miR-130a and miR-27b have been shown to promote osteogenic differentiation by targeting PPAR γ and enhancing the expression of *Runx2* and *OSX* genes.⁵³



Recently, Jin *et al.* have demonstrated that miR-145 is able to decrease osteogenic differentiation of human jaw bone marrow mesenchymal stem cells by targeting semaphorin 3A.⁵⁴ Moreover, miR-21,⁵⁵ miR-148b-3p,⁵⁶ Mmu-miR-185,⁵⁷ and miR-381⁵⁸ have also show important roles in regulating osteogenic differentiation of hMSCs. Thus, numerous miRNAs play important role in regulating osteogenic differentiation of MSCs, showing either positive or negative regulatory role.

4.2 MiRNAs and adipogenic differentiation of MSCs

Adipogenesis is another differentiation direction of MSCs and several key transcription factors are involved, including peroxisome proliferator-activated receptor γ (PPAR γ) and CCAAT/enhancer binding proteins (C/EBPs). MiRNAs also show key role in regulating adipogenic differentiation of MSCs. MiR-27a inhibits adipocyte differentiation by targeting 3'-UTR of PPAR γ in a sequence-specific manner, and miR-223 regulates adipocyte differentiation *via* a C/EBPs/miR-223/FGFR2 regulatory feedback loop.^{59,60} Recent study has shown that miR-214-5p promotes adipogenic differentiation but inhibits osteogenic differentiation of hBMSCs. Overexpression of miR-214-5p promoted adipogenic differentiation, inhibited the mRNA expression of osteogenic genes *ALP*, *Runx2*, *OCN* and *collagen α -1 (I) chain (COL1A1)*, and suppressed the level of transforming growth factor- β (TGF- β), phosphorylated-Smad2 (p-Smad2) and collagen type IV α 1 chain (COL4A1) in hBMSC. These findings suggest that miR-214-5p promotes the adipogenic differentiation of hBMSCs by regulating TGF- β /Smad2/COL4A1 signaling pathway.⁶¹ Moreover, miRNAs also function through mitogen-activated protein kinase (MAPK) signaling to regulate adipogenic differentiation and commitment. Jin *et al.* have reported that MAPK7 plays a major role in guiding miR-24 and miR-143 to promote 3T3-L1 adipogenesis differentiation and commitment.⁶² MAP2K5 (mitogen-activated protein kinase 5), which is another novel member of the MAPK signaling pathway, has the positive effect of modulating adipose tissue-derived stromal cells (ADSC) differentiation by miRNA-143.⁶³ In addition, miR-148a and miR-210 inhibit Wnt signaling pathway by targeting Wnt1 and Tcf7l2 (transcription factor 7 like 2) respectively, and ultimately promote adipogenic differentiation of ADSCs.^{64,65} Therefore, Wnt signaling pathway is also a crucial signaling pathway that targets miRNA-mediated adipogenic differentiation.

4.3 MiRNAs and chondrogenic differentiation of MSCs

Numerous evidence suggests that miRNAs are indispensable for chondrocyte differentiation and cartilage function.⁶⁶ Yan *et al.* have revealed that 44 miRNAs are involved in cartilage differentiation by using microRNA array detection. Further, two miRNAs out of seven differentially-expressed miRNAs, called miR-29a and miR-29b, have been revealed to directly target 3' UTR of *col2a1* encoding type II collagen α 1, suggesting them as key regulators for chondrogenic differentiation of mMSCs.⁶⁷ Moreover, the expression of miR-29a and miR-29b is demonstrated to be regulated by SRY-related high mobility group-box gene 9 (Sox9), a key transcription factor for chondrocyte.⁶⁷ Guerit *et al.* have also

found that the expression of miRNA-574-3p is regulated by Sox9 and miRNA-574-3p inhibits chondrogenic differentiation of hMSCs.⁶⁸ However, some studies show that Sox9 is a target of miRNAs to regulate chondrogenic differentiation of MSCs. MiR-495 suppresses chondrogenic differentiation of hMSCs by directly binding to 3' UTR of Sox9 and reducing Sox9 expression.⁶⁹ These findings reveal the complexity of miRNAs function. Furthermore, both miR-181a and miR-181b negatively regulate cartilage differentiation and function in maintaining cell integrity. Besides, their negative feedback regulation has gradually become an effective therapeutic target for cartilage-related diseases.^{70,71} Zhong *et al.* have reported that miR-377 is directly bound up with chondrogenesis through regulating TGFBR2 expression and enhancement of miR-377 modulates cartilage-specific genes expression, providing an important clue for research in arthritis pathogenesis and new treatment method for arthritis.⁷² Therefore, miRNAs are key regulators for chondrogenic differentiation of MSCs and can be novel targets for treatment of cartilage-related diseases.

4.4 MiRNAs and other cell types differentiation of MSCs

Besides being involved in the regulation of the inherent multipotent differentiation potential of MSCs to osteoblasts, adipocytes and chondrocytes, miRNAs also show key role in regulating the differentiation of MSCs to other cell types, such as hepatocytes, cardiomyocytes and nerve cells. Cui *et al.* have screened six overexpressed miRNAs (miR-1246, miR-1290, miR-148a, miR-30a, miR-424 and miR-542-5p) during hepatic differentiation of human umbilical cord lining-derived mesenchymal stem cells (hMSCs). They found that downregulation of any one of the six miRNAs inhibited hepatocyte growth factor (HGF)-induced hepatic differentiation and ectopic overexpression of seven miRNAs (miR-1246, miR-1290, miR-148a, miR-30a, miR-424, miR-542-5p and miR-122) together stimulated hMSC conversion into functionally mature induced hepatocytes.⁷³ Moreover, the transplantation of the induced hepatocytes into mice with liver injury not only improved liver function, but also restored injured livers.⁷³ These findings indicate the capability of miRNAs converting hMSCs to hepatocytes. Chen *et al.* have also reported the therapeutic potential of miRNA in treating acute myocardial infarction by modulating MSC function.⁷⁴ They found that overexpression of miR-133 decreased apoptosis of rat MSCs (rMSCs) and enhanced the therapeutic effect of rMSCs in a rat model with myocardial infarction.⁷⁴ MicroRNA let-7f-5p has been shown to target partitioning defective 6 homologue alpha (Par6 α), a component of the Par3/Par6/aPKC complex, which is essential for axon specification during neuronal development. Downregulation of let-7f-5p in rat BMSCs induces the cells into neuron-like cells by directly targeting Par6 α .⁷⁵ More recently, key miRNAs and related pathways involved in neural differentiation of rBMSCs have been revealed by Wei *et al.*⁷⁶ They identified 83 significantly differentially expressed miRNAs during neural differentiation of rBMSCs and showed that Hippo, Wnt, TGF- β and Hedgehog signaling pathways were involved in the neural differentiation.⁷⁶ All these findings demonstrate the key role of



miRNAs in regulating differentiation of MSCs into other cell types rather than osteoblast, adipocyte, and chondrocyte and provide potential targets for MSCs-based cell therapy.

5 LncRNAs and MSC differentiation

Recently, with the fast advances in lncRNAs research, evidences have shown that lncRNAs are widely involved in the growth and development by regulating the fate of MSCs.⁷⁷

5.1 LncRNAs and osteogenic differentiation of MSCs

Possessing complicated characteristics and action modes, lncRNAs show a more complex regulatory role in osteogenic differentiation of MSCs compared with miRNAs. lncRNAs regulate osteogenic differentiation through regulating signaling pathways, acting as “miRNA sponge”, targeting miRNAs, or functioning in other ways. Jia *et al.* have reported that canonical Wnt signaling pathway is activated by ANCR-RNAi, and low level of ANCR promotes the process of osteogenic differentiation in periodontal ligament stem cells (PDLSCs).⁷⁸ By acting as “miRNA sponge”, lncRNAs play important role in mediating osteogenic differentiation of MSCs. It has been demonstrated that the expression level of lncRNA-H19 gradually increases during osteogenic differentiation of both hBMSCs and mBMSCs. Further investigation shows that lncRNA-H19 promotes osteogenic differentiation by sponging various miRNAs, including miR-188,⁷⁹ miR-138,⁸⁰ and miR-675.⁸¹ Moreover, lncRNAs also function by targeting miRNAs. lncRNAs HULC and MALAT1 promote osteoblast differentiation of hBMSCs either by targeting miR-195 or by targeting miRNA-143.^{82,83} lncRNA-ANCR inhibits osteogenic differentiation of PDLSCs by targeting miRNA-758, which has a role in promoting Notch2 expression by targeting 3'-UTR of Notch2.⁸⁴ Other findings show different functional ways of lncRNAs in regulating osteogenic differentiation of MSCs. lncRNA TUG1 promotes osteogenic differentiation of PDLSCs through interacting with lin-28 homolog A (Lin28A), which is a potential target for TUG1-mediated bone formation analyzed by bioinformatics.⁸⁵ lncRNA AK141205 positively regulates osteogenic differentiation of mMSCs by promoting CXCL13 expression via acetylation of H4 histone, providing a potential therapeutic target of disease treatment using MSCs.⁸⁶ Zhuang *et al.* have found that lncRNA MEG3 promotes osteogenic differentiation of hMSCs partly by activating BMP4 transcription,⁸⁷ while Jin *et al.* have shown that knockdown of lncRNA myocardial infarction-associated transcript (MIAT) promotes osteogenic differentiation of human adipose stem cells (hASCs) both *in vitro* and *in vivo*, suggesting that lncRNA MIAT negatively regulates osteogenic differentiation.⁸⁸ These findings provide reference for studying the mechanism by which lncRNAs mediate osteogenic differentiation of MSCs and provide new therapeutic targets for treating diseases.

5.2 LncRNAs and adipogenic differentiation of MSCs

In most cases, lncRNAs act in two opposite processes including osteogenic differentiation and adipogenic differentiation.

Therefore, some lncRNAs involved in the regulation of osteogenic differentiation of MSCs are also involved in the regulation of adipogenic differentiation of MSCs.^{89,90} lncRNA H19 regulates adipogenic differentiation by targeting miR-675 and is significantly down-regulated in human BMSCs differentiated into adipocytes through a CTCF/H19/miR-675/HDAC axis.⁹¹ Similarly, lnc-ADNCR has been shown to inhibit adipogenic differentiation by competing with miRNA-204 which is also called “miRNA sponge”. miRNA-204 inhibits adipocyte differentiation by suppressing PPAR γ activity.⁹² lncRNA Gm15290 facilitates PPAR γ - and C/EBP α -induced fat deposition by targeting miR-27b and results in a significant increase in body weight in mice.⁹³ Li *et al.* found that lnc-GAS5 overexpression negatively regulated the formation of fat cells. The mechanism is that lnc-GAS5 acts as an endogenous competitive RNA to inhibit the binding sites of miR-18a. This process reduces the expression of connective tissue growth factor (CTGF), thereby negatively modulating the adipogenic differentiation of MSCs.⁹⁴ In addition, lncRNA-Para1 activates PPAR γ to promote adipogenic differentiation by interacting with paraspeckle component and hnRNP-like RNA binding protein 14 (RBM14/NCoA).⁹⁵ Recently, Gernapudi and colleagues have identified a novel miR-140/lncRNA NEAT1 signaling network necessary for adipogenesis by using adipocyte-derived stem cells (ADSCs) from wild-type and miR-140 knockout mice.⁹⁶ They found that miR-140 knockout ADSCs showed dramatically decreased adipogenic capabilities associated with down-regulation of NEAT1 expression. Further, they demonstrated that miR-140 promoted NEAT1 expression by physically binding to it, which promotes adipogenic differentiation of mADSCs.⁹⁶ lncRNA HOXA11-AS1 and MIR31HG also show promotion effect on adipogenic differentiation of hADSCs.^{97,98} All these findings reveal the important role of lncRNAs in regulating adipogenic differentiation of MSCs and provide potential therapy targets for diseases, such as obesity.

5.3 LncRNAs and chondrogenic differentiation of MSCs

Compared with a large number of lncRNAs involved in osteogenic differentiation and adipogenic differentiation of MSCs, there are few studies on the role of lncRNAs in the regulation of chondrogenic differentiation of MSCs. It has been reported that Sox4 promotes proliferation and chondrogenesis of human Synovium-derived MSCs (SMSCs) by up-regulating lncRNA DANCER.⁹⁹ Further study has revealed that lncRNA DANCER promotes proliferation and chondrogenesis of human SMSCs by targeting myc, Smad3, and STAT3 to regulate their stability.¹⁰⁰ As a transcription factor of the same family, SOX9, which plays a role in regulating cartilage formation under the mediation of lncRNA-ROCR. In the absence of ROCR, SOX9 induction was significantly abolished, while overexpression of SOX9 promoted differentiation of MSCs into chondrocytes. Therefore, the important role of lncRNA-ROCR in chondrocyte biology has been revealed.¹⁰¹ Apart from this, studies have found that lncRNA-ZBED3-AS1 can promote cartilage formation by up-regulating the expression of zbed3. This pathway acts primarily through the Wnt/ β -catenin pathway, so the Wnt



Table 1 MiRNAs and lncRNAs involved in determining cell fate of MSC

Type	Name	Cell fate determination of MSCs	Main mechanism	Key references
MiRNA	miR-346	Promotes osteogenic differentiation	Suppresses the expression of GSK-3 β protein and activates the Wnt/ β -catenin pathway	45
	miR-155	Inhibits osteogenic differentiation	Targets Runx2 and BMPR2, and downregulates their expression	48
	miR-181a	Promotes osteoblast differentiation	Targets the negative regulator of Tgfb1 and T β R-I/Alk5 to degrade it	49
	miR-34a	Inhibits osteogenic differentiation	Reduces the expression of JAG1 of the ligand for Notch1	52
	miR-130a and miR-27b	Promote osteogenic differentiation	Promote the expression of <i>Runx2</i> and <i>Osterix</i> and inhibit the expression of PPAR γ	53
	miR-145	Inhibits osteogenic differentiation	Targets semaphorin 3A	54
	miR-21	Promotes osteogenic differentiation	Inhibits the BMP/Smads signaling pathway under the interaction of Smad7. Promotes maxillofacial bone regeneration <i>via</i> the PTEN/PI3K/Akt/HIF-1 α pathway	50 and 55
	miR-148b-3p	Promotes osteogenic differentiation	Increases alkaline phosphatase and collagen type I	56
	Mmu-miR-185	Promotes osteogenic differentiation	<i>Via</i> the Bgn-mediated BMP/Smad pathway	57
	miR-381	Inhibits osteogenic differentiation	Upregulates PPAR γ <i>via</i> suppressing Wnt signaling pathway	58
	miR-27a	Inhibits adipocyte differentiation	Targets 3' UTR of PPAR γ to degrade it	52
	miR-223	Regulates adipocyte and osteoblast differentiation	Targets a novel C/EBPs/miR-223/FGFR2 regulatory feedback loop	53
	miR-214-5p	Promotes adipogenic differentiation; attenuates the osteogenic differentiation	Promotes adipogenic differentiation by regulating TGF- β /Smad2/COL4A1 signaling pathway; inhibits ALP, Runx2, OC and COL1 expression	61
	miR-143	Promotes adipogenesis differentiation	Targets the MAPK7 to repress it	62
	miR-148a	Promotes adipogenic differentiation	Represents a CREB-modulated miRNA that acts to repress Wnt1	57
	miR-210	Promotes adipogenic differentiation	Promotes adipogenesis by repressing Wnt signaling through targeting Tcf7l2	58
	miR-29a and miR 29b	Inhibits cartilage differentiation	Target 3' UTR of Col2a1 encoding type II collagen	67
	miR-495 and miRNA-574-3p	Suppress chondrogenic differentiation	Target Sox9	68 and 69
	miR-181a	Suppress cartilage differentiation	Suppresses the expression of two genes, CCN1 and a major cartilaginous proteoglycan, aggrecan;	63
	miR-181b	Suppress cartilage differentiation	Reduces MMP-13 expression while inducing type II collagen expression	64
	miR-377	Promotes chondrogenic differentiation	Regulates TGFB2 expression and modulates the expression of cartilage-specific genes such as AGC1 in C-28/I2	72
	miR-1246, miR-1290, miR-148a, miR-30a, miR-424 and miR-542-5p	Promote differentiation into hepatocytes	Unknown	73
	miR-133	Promotes differentiation into cardiomyocytes	Decreases cell apoptosis	74
	let-7f-5p	Promotes differentiation into nerve-like-cells	Directly targets Par6 α	75



Table 1 (Contd.)

Type	Name	Cell fate determination of MSCs	Main mechanism	Key references
lncRNA	lncRNA-ANCR	Inhibits osteogenic differentiation	Targets miR-758 and miR-758, regulates Notch2 expression by targeting 3'-UTR of Notch2, Wnt signaling pathway is activated by lncRNA-ANCR/RNAi	78 and 84
	lncRNA H19	Promotes osteogenic differentiation	Mediates LCoR through sponging miR-188	79
	lncRNA-HULC and lncRNA-MALAT1	Promote osteoblast differentiation	lncRNA-HULC acts through sponging miR-195 and enhances activation of Wnt/ β -catenin and p38MAPK pathway; lncRNA – MALAT1 regulates Osx expression through targeting miR-143	82 and 83
	TUG1	Promotes osteogenic differentiation	Promotes osteogenic differentiation through suppressing Lin28A	85
	lncAK141205	Facilitates osteogenic differentiation	lncAK141205 promotes CXCL13 expression by acetylation of H4 histone	86
	lncRNA MIAT	Inhibits osteogenic differentiation	Unknown	88
	lncRNA H19	Inhibits adipogenic differentiation	Sponge microRNA-675 and miR-675 targets the 3' UTRs of the histone deacetylase (HDAC) 4–6 transcripts	91
	lnc-ADNCR	Inhibits adipogenic differentiation	Through sponging miR-204 and promotes the expression of SIRT1, then the NCoR and SMART were blocked to repress PPAR γ activity	92
	lncRNA Gm15290	Promotes adipogenic differentiation	Sponges miR-27b to promote PPAR γ activity	93
	lnc-GAS5	Inhibits adipogenic differentiation	Acts as a sponge for miR-18a and suppresses CTGF protein translation	94
	lincRNA-Para1	Promote adipogenic differentiation	Activates the PPAR γ through interacting with the RBM14/NCoAA	95
	lncRNA NEAT1	Promotes adipogenic differentiation	Interacts with NEAT1 and lead to increase NEAT1 expression	96
	lncRNA HOXA11-AS1	Promotes adipogenic differentiation	Suppresses the transcription genes of CEBP- α , DGAT2, CIDEC, and perilipin	97
	lncRNA MIR31HG	Inhibits adipocyte differentiation	Reduces the enrichment of active H3K4me3 and AcH3, FABP4	98
	lncRNA-DANCR	Promotes proliferation and chondrogenesis	Upregulates the expression of Smad3 and STAT3	100
	lncRNA-ROCR	Promotes proliferation and chondrogenesis	Upregulates SOX9	101
	lncRNA-ZBED3-AS1	Promotes cartilage formation	Increases zbed3 expression	102
	lncRNA H19	Promotes chondrogenic differentiation	Competes miRNA regulation of STAT2	103
	lncRNA MIAT	Promotes differentiation into endothelial cells	Targets miR-200a	104
	lncRNA MEG3	Promotes differentiation into endothelial cells	Decreases VEGF expression <i>via</i> facilitating FOXM1 ubiquitination	105
	lncRNA MALAT1	Promotes differentiation hepatocytes	β -Catenin-coordinated lncRNA MALAT1/ miR-217 axis	106
	lncRNA Braveheart	Promotes differentiation into cardiomyocytes	Enhances the expression of cardiac-specific transcription factors and EMT-associated genes	107
	lncRNA H19	Promotes differentiation into nerve cells	Function through miRNA-675/IGFR axis	108

inhibitor Dickkopf-1 (DKK1) reverses the stimulatory effect of ZBED3-AS1 on cartilage formation.¹⁰² Recently, Pang *et al.* have revealed the role of lncRNA H19 in regulating chondrogenic differentiation of ADSCs.¹⁰³ They found that overexpression of

lncRNA H19 in ADSCs induced differentiation towards chondrocytes by competing miRNA regulation of STAT2.¹⁰³ All these findings gradually uncover the role of lncRNAs in chondrogenic



differentiation and provide potential targets for chondrocyte-related diseases.

5.4 lncRNAs and other cell types differentiation of MSCs

There are emerging evidences illustrating the regulatory role of lncRNAs in differentiation of MSCs into other cell types, although they are still rare in comparison to the studies on the three well-known osteogenic, adipogenic and chondrogenic differentiation. Wang *et al.* have reported that lncRNA MIAT promotes rBMSCs differentiation into endothelial cells by regulating vascular endothelial growth factor (VEGF) *via* targeting miR-200a, which restores erectile dysfunction in rat.¹⁰⁴ Sun and colleagues have demonstrated another lncRNA, lncRNA MEG3, involved in regulating the differentiation of rBMSCs to endothelial cells.¹⁰⁵ They showed that down-regulation of lncRNA MEG3 promoted BMSCs differentiation into endothelial cells by decreasing VEGF expression *via* facilitating forkhead box protein M 1 (FOXO1) ubiquitination, resulting in the repair of erectile dysfunction.¹⁰⁵ Recently, Tan *et al.* used HGF to induce rMSCs to differentiate into hepatocytes. They found that β -catenin-coordinated lncRNA MALAT1/miR-217 axis up-regulated the expression of zinc finger E-box-binding homeobox 1 (ZEB-1) and further enhanced the telomerase activity by regulating telomerase reverse transcriptase (TERT) in rMSCs differentiating into hepatocytes.¹⁰⁶ Moreover, lncRNA Braveheart can facilitate mMSCs differentiation into cardiomyocytes by magnifying the expression of cardiac-specific transcription factors and epithelial-mesenchymal transition (EMT)-associated genes, providing new clue for cell-mediated cardiomyocyte regeneration using lncRNA.¹⁰⁷ Moreover, lncRNA H19 regulates the differentiation of hMSCs into nerve cells through the miRNA-675/IGF1R axis.¹⁰⁸ Wu *et al.* have revealed the expression patterns of lncRNAs in rBMSCs during their differentiation into neural cells.¹⁰⁹ All these findings show the key involvement of lncRNAs in differentiation of MSCs to other cell types besides osteoblast, adipocyte and chondrocyte.

6 Conclusion and perspectives

MSCs have become a favorite source of cell-based therapy for their multipotency and plasticity to differentiate into multiple cell types, including well-known inherent osteoblasts, adipocytes, and chondrocytes, and other cell types such as hepatocytes, cardiomyocytes and nerve cells. Therefore, uncovering the mechanism that determining cell fate of MSCs is important for better understanding MSCs and manipulating them for clinical application. Here, we highlight the key role of miRNAs and lncRNAs in cell fate determination of MSCs, not only focusing on the well-known inherent osteoblast, adipocyte and chondrocyte differentiation, but also introducing the differentiation of MSCs to hepatocyte, cardiomyocyte and nerve cell, respectively. Based on the numerous recent advances, we know that miRNAs and lncRNAs are key regulators in determining cell fate of MSCs by modulating their target gene expression or signaling transduction. Many molecules and signaling pathways (*e.g.* Wnt/ β -catenin signaling, BMP signaling, and Notch signaling)

have been demonstrated to be involved in (Table 1). Besides, there are interactions between some miRNAs and lncRNAs in cell fate determination of MSCs. Thus, the role of miRNAs and lncRNAs in MSCs attracts more and more attention.

With the gradual uncovering of the critical regulatory role and underlying mechanism of miRNAs and lncRNAs in regulating cell fate determination of MSCs, more and more aspects of miRNAs and lncRNAs have been known, which make them as potential targets for modulating MSCs or treating disease. However, there are still lots of questions to be answered. How is the miRNA and lncRNA expression regulated during MSCs differentiation? Are there some main sets of miRNAs or lncRNAs involved in cell fate determination of MSCs? As there is interaction between miRNAs and lncRNAs, what is their relationship during MSCs differentiation? Future study should target these kinds of questions to clearly clarify the regulatory mechanism of some specific miRNAs and lncRNAs in differentiation of MSCs. Most important, as many evidences reveal that there are miRNAs networks, lncRNAs networks, or miRNAs-lncRNAs interaction networks involved in the regulation of cell function, physiological and pathological processes, these networks should be identified and their functions should be uncovered in cell fate determination of MSCs, which will be the future research targets.

In summary, miRNAs and lncRNAs are novel and critical regulators for the cell fate determination of MSCs. The uncovering of the molecular mechanisms of miRNAs and lncRNAs determining cell fate of MSCs and the modulation of MSCs by targeting miRNAs or lncRNAs to facilitate clinical application of MSCs are attractive research areas.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81772017, 31570940), the China Postdoctoral Science Foundation (2018T111099, 2017M610653), Young Talent Fund of University Association for Science and Technology in Shaanxi, China (20170401), The Project Supported by Natural Science Basic Research Plan in Shaanxi Province of China (2018JM3040), the grant (BKJ17J004).

References

- 1 M. P. Alfaro, S. Saraswati and P. P. Young, *Vitam. Horm.*, 2011, **87**, 39–59.
- 2 R. Litwinowicz, B. Kapelak, J. Sadowski, A. Kedziora and K. Bartus, *Polish Journal of Thoracic and Cardiovascular Surgery*, 2018, **15**, 196–199.
- 3 Y. Z. Jin and J. H. Lee, *Clinics in Orthopedic Surgery*, 2018, **10**, 271–278.
- 4 S. Hamidian Jahromi and J. E. Davies, *Stem Cells Transl. Med.*, 2019, **8**, 456–465.



- 5 J. X. Yang, R. H. Rastetter and D. Wilhelm, *Adv. Exp. Med. Biol.*, 2016, **886**, 13–32.
- 6 S. Crippa, M. Cassano and M. Sampaolesi, *Curr. Pharm. Des.*, 2012, **18**, 1718–1729.
- 7 J. Li, H. Tian, J. Yang and Z. Gong, *DNA Cell Biol.*, 2016, **35**, 459–470.
- 8 J. Chen, M. Qiu, C. Dou, Z. Cao and S. Dong, *Drug Dev. Res.*, 2015, **76**, 235–245.
- 9 T. Moghaddam and Z. Neshati, *J. Cell. Biochem.*, 2019, **120**, 14136–14155.
- 10 D. W. Trobaugh and W. B. Klimstra, *Trends Mol. Med.*, 2017, **23**, 80–93.
- 11 N. Ludwig, P. Leidinger, K. Becker, C. Backes, T. Fehlmann, C. Pallasch, S. Rheinheimer, B. Meder, C. Stahler, E. Meese and A. Keller, *Nucleic Acids Res.*, 2016, **44**, 3865–3877.
- 12 Q. Lin, L. Ma, Z. Liu, Z. Yang, J. Wang, J. Liu and G. Jiang, *Oncotarget*, 2017, **8**, 15961–15970.
- 13 B. P. Towler, C. I. Jones and S. F. Newbury, *Biochem. Soc. Trans.*, 2015, **43**, 1208–1214.
- 14 N. Shomron and C. Levy, *J. Biomed. Biotechnol.*, 2009, **2009**, 594678.
- 15 Y. Lee, M. Kim, J. Han, K. H. Yeom, S. Lee, S. H. Baek and V. N. Kim, *EMBO J.*, 2004, **23**, 4051–4060.
- 16 V. N. Kim and J. W. Nam, *Trends Genet.*, 2006, **22**, 165–173.
- 17 V. M. King and G. M. Borchert, *Methods Mol. Biol.*, 2017, **1617**, 27–37.
- 18 C. Shin, J. W. Nam, K. K. Farh, H. R. Chiang, A. Shkumatava and D. P. Bartel, *Mol. Cell*, 2010, **38**, 789–802.
- 19 S. Hosseinpour, Y. He, A. Nanda and Q. Ye, *Calcif. Tissue Int.*, 2019, **105**, 223–238.
- 20 J. O'Brien, H. Hayder, Y. Zayed and C. Peng, *Front. Endocrinol.*, 2018, **9**, 402.
- 21 S. Dahariya, I. Paddibhatla, S. Kumar, S. Raghuwanshi, A. Pallepatti and R. K. Gutti, *Mol. Immunol.*, 2019, **112**, 82–92.
- 22 B. K. Dey, A. C. Mueller and A. Dutta, *Transcription*, 2014, **5**, e944014.
- 23 T. R. Mercer, M. E. Dinger and J. S. Mattick, *Nat. Rev. Genet.*, 2009, **10**, 155–159.
- 24 V. J. Peschansky and C. Wahlestedt, *Epigenetics*, 2014, **9**, 3–12.
- 25 H. Wu, L. Yang and L. L. Chen, *Trends Genet.*, 2017, **33**, 540–552.
- 26 Y. Hori, Y. Tanimoto, S. Takahashi, T. Furukawa, K. Koshiba-Takeuchi and J. K. Takeuchi, *BMC Genomics*, 2018, **19**, 967.
- 27 K. C. Wang and H. Y. Chang, *Mol. Cell*, 2011, **43**, 904–914.
- 28 F. Leti and J. K. DiStefano, *Genes*, 2017, **8**, 207.
- 29 M. Huarte, M. Guttman, D. Feldser, M. Garber, M. J. Koziol, D. Kenzelmann-Broz, A. M. Khalil, O. Zuk, I. Amit, M. Rabani, L. D. Attardi, A. Regev, E. S. Lander, T. Jacks and J. L. Rinn, *Cell*, 2010, **142**, 409–419.
- 30 X. Li, Z. Wu, X. Fu and W. Han, *Mutat. Res., Rev. Mutat. Res.*, 2014, **762**, 1–21.
- 31 L. Da Sacco, A. Baldassarre and A. Masotti, *Int. J. Mol. Sci.*, 2012, **13**, 97–114.
- 32 L. Yang, H. Wang, Q. Shen, L. Feng and H. Jin, *Cell Death Dis.*, 2017, **8**, e3073.
- 33 M. C. Tsai, O. Manor, Y. Wan, N. Mosammaparast, J. K. Wang, F. Lan, Y. Shi, E. Segal and H. Y. Chang, *Science*, 2010, **329**, 689–693.
- 34 P. Walter and G. Blobel, *Nature*, 1982, **299**, 691–698.
- 35 M. T. Lam, W. Li, M. G. Rosenfeld and C. K. Glass, *Trends Biochem. Sci.*, 2014, **39**, 170–182.
- 36 N. W. Mathy and X. M. Chen, *J. Biol. Chem.*, 2017, **292**, 12375–12382.
- 37 L. Hu, C. Yin, F. Zhao, A. Ali, J. Ma and A. Qian, *Int. J. Mol. Sci.*, 2018, **19**, 360.
- 38 D. Hamam, D. Ali, M. Kassem, A. Aldahmash and N. M. Alajez, *Stem Cells Dev.*, 2015, **24**, 417–425.
- 39 C. Huang, J. Geng and S. Jiang, *Cell Tissue Res.*, 2017, **368**, 229–238.
- 40 I. D'Alimonte, A. Lannutti, C. Pipino, P. Di Tomo, L. Pierdomenico, E. Cianci, I. Antonucci, M. Marchisio, M. Romano, L. Stuppia, F. Caciagli, A. Pandolfi and R. Ciccarelli, *Stem Cell Rev.*, 2013, **9**, 642–654.
- 41 J. D. Lamplot, J. Qin, G. Nan, J. Wang, X. Liu, L. Yin, J. Tomal, R. Li, W. Shui, H. Zhang, S. H. Kim, W. Zhang, J. Zhang, Y. Kong, S. Denduluri, M. R. Rogers, A. Pratt, R. C. Haydon, H. H. Luu, J. Angeles, L. L. Shi and T. C. He, *Am. J. Stem Cells*, 2013, **2**, 1–21.
- 42 Y. Peng, Q. Kang, H. Cheng, X. Li, M. H. Sun, W. Jiang, H. H. Luu, J. Y. Park, R. C. Haydon and T. C. He, *J. Cell. Biochem.*, 2003, **90**, 1149–1165.
- 43 F. Sun, M. Wan, X. Xu, B. Gao, Y. Zhou, J. Sun, L. Cheng, O. D. Klein, X. Zhou and L. Zheng, *J. Dent. Res.*, 2014, **93**, 589–595.
- 44 M. Zhang, Y. Q. Bian, H. M. Tao, X. F. Yang and W. D. Mu, *Eur. Rev. Med. Pharmacol. Sci.*, 2018, **22**, 2896–2905.
- 45 Q. Wang, J. Cai, X. H. Cai and L. Chen, *PLoS One*, 2013, **8**, e72266.
- 46 S. Mori, H. Yoshikawa, J. Hashimoto, T. Ueda, H. Funai, M. Kato and K. Takaoka, *Bone*, 1998, **22**, 99–105.
- 47 A. Nohe, *Cell. Signalling*, 2004, **16**, 291–299.
- 48 H. Liu, L. Zhong, T. Yuan, S. Chen, Y. Zhou, L. An, Y. Guo, M. Fan, Y. Li, Y. Sun, W. Li, Q. Shi and Y. Weng, *Int. J. Mol. Med.*, 2018, **41**, 3379–3393.
- 49 R. Bhushan, J. Grunhagen, J. Becker, P. N. Robinson, C. E. Ott and P. Knaus, *Int. J. Biochem. Cell Biol.*, 2013, **45**, 696–705.
- 50 Q. Song, L. Zhong, C. Chen, Z. Tang, H. Liu, Y. Zhou, M. Tang, L. Zhou, G. Zuo, J. Luo, Y. Zhang, Q. Shi and Y. Weng, *Int. J. Mol. Med.*, 2015, **36**, 1497–1506.
- 51 J. Cao, Y. Wei, J. Lian, L. Yang, X. Zhang, J. Xie, Q. Liu, J. Luo, B. He and M. Tang, *Int. J. Mol. Med.*, 2017, **40**, 378–388.
- 52 L. Chen, K. Holmström, W. Qiu, N. Ditzel, K. Shi, L. Hokland and M. Kassem, *Stem Cells*, 2014, **32**, 902–912.
- 53 K. Seenprachawong, T. Tawornsawutruk, C. Nantasenamat, P. Nuchnoi, S. Hongeng and A. Supokawej, *Front. Genet.*, 2018, **9**, 543.
- 54 Y. Jin, F. Hong, Q. Bao, Q. Xu, R. Duan, Z. Zhu, W. Zhang and C. Ma, *Connect. Tissue Res.*, 2019, 1–9.



- 55 C. Yang, X. Liu, K. Zhao, Y. Zhu, B. Hu, Y. Zhou, M. Wang, Y. Wu, C. Zhang, J. Xu, Y. Ning and D. Zou, *Stem Cell Res. Ther.*, 2019, **10**, 65.
- 56 S. Mollazadeh, B. S. F. Bazzaz, V. Neshati, A. A. de Vries, H. Naderi-Meshkin, M. Mojarad, M. Mirahmadi, Z. Neshati and M. A. Kerachian, *BMC Med. Genet.*, 2019, **20**, 117.
- 57 Q. Cui, J. Xing, M. Yu, Y. Wang, J. Xu, Y. Gu, X. Nan, W. Ma, H. Liu and H. Zhao, *Cell Death Dis.*, 2019, **10**, 172.
- 58 H. Long, Y. Zhu, Z. Lin, J. Wan, L. Cheng, M. Zeng, Y. Tang and R. Zhao, *Cell Death Dis.*, 2019, **10**, 470.
- 59 Y. H. Son, S. Ka, A. Y. Kim and J. B. Kim, *Endocrinol. Metab.*, 2014, **29**, 122–135.
- 60 X. Guan, Y. Gao, J. Zhou, J. Wang, F. Zheng, F. Guo, A. Chang, X. Li and B. Wang, *Stem Cells*, 2015, **33**, 1589–1600.
- 61 J. Qiu, G. Huang, N. Na and L. Chen, *Mol. Med. Rep.*, 2018, **17**, 6301–6310.
- 62 M. Jin, Y. Wu, J. Wang, J. Chen, Y. Huang, J. Rao and C. Feng, *Biochem. Biophys. Res. Commun.*, 2016, **474**, 76–82.
- 63 L. Chen, J. Hou, L. Ye, Y. Chen, J. Cui, W. Tian, C. Li and L. Liu, *Sci. Rep.*, 2014, **4**, 3819.
- 64 C. Shi, M. Zhang, M. Tong, L. Yang, L. Pang, L. Chen, G. Xu, X. Chi, Q. Hong, Y. Ni, C. Ji and X. Guo, *Sci. Rep.*, 2015, **5**, 9930.
- 65 L. Qin, Y. Chen, Y. Niu, W. Chen, Q. Wang, S. Xiao, A. Li, Y. Xie, J. Li, X. Zhao, Z. He and D. Mo, *BMC Genomics*, 2010, **11**, 320.
- 66 E. Hong and A. H. Reddi, *Tissue Eng., Part B*, 2012, **18**, 445–453.
- 67 C. Yan, Y. Wang, X. Y. Shen, G. Yang, J. Jian, H. S. Wang, G. Q. Chen and Q. Wu, *Biomaterials*, 2011, **32**, 6435–6444.
- 68 D. Guerit, D. Philipot, P. Chuchana, K. Toupet, J. M. Brondello, M. Mathieu, C. Jorgensen and D. Noel, *PLoS One*, 2013, **8**, e62582.
- 69 S. Lee, D. S. Yoon, S. Paik, K. M. Lee, Y. Jang and J. W. Lee, *Stem Cells Dev.*, 2014, **23**, 1798–1808.
- 70 K. Sumiyoshi, S. Kubota, T. Ohgawara, K. Kawata, T. Abd El Kader, T. Nishida, N. Ikeda, T. Shimo, T. Yamashiro and M. Takigawa, *J. Cell. Biochem.*, 2013, **114**, 2094–2100.
- 71 J. Song, M. Lee, D. Kim, J. Han, C. H. Chun and E. J. Jin, *Biochem. Biophys. Res. Commun.*, 2013, **431**, 210–214.
- 72 N. Zhong, J. Sun, Z. Min, W. Zhao, R. Zhang, W. Wang, J. Tian, L. Tian, J. Ma, D. Li, Y. Han and S. Lu, *Osteoarthritis and Cartilage*, 2012, **20**, 593–602.
- 73 L. Cui, Y. Shi, X. Zhou, X. Wang, J. Wang, Y. Lan, M. Wang, L. Zheng, H. Li and Q. Wu, *Cell Death Dis.*, 2013, **4**, e918.
- 74 Y. Chen, Y. Zhao, W. Chen, L. Xie, Z.-A. Zhao, J. Yang, Y. Chen, W. Lei and Z. Shen, *Stem Cell Res. Ther.*, 2017, **8**, 268.
- 75 L. Han, Y. Wang, L. Wang, B. Guo, S. Pei and Y. Jia, *Biochem. Biophys. Res. Commun.*, 2018, **495**, 1476–1481.
- 76 Z.-J. Wei, B.-Y. Fan, Y. Liu, H. Ding, H.-S. Tang, D.-Y. Pan, J.-X. Shi, P.-Y. Zheng, H.-Y. Shi, H. Wu, A. Li and S.-Q. Feng, *Neural Regen. Res.*, 2019, **14**, 1462–1469.
- 77 Z. Y. Xie, P. Wang, Y. F. Wu and H. Y. Shen, *World Journal of Stem Cells*, 2019, **11**, 167–179.
- 78 Q. Jia, W. Jiang and L. Ni, *Arch. Oral Biol.*, 2015, **60**, 234–241.
- 79 Y. Wang, W. Liu, Y. Liu, J. Cui, Z. Zhao, H. Cao, Z. Fu and B. Liu, *J. Cell. Physiol.*, 2018, **233**, 7435–7446.
- 80 J. Wu, J. Zhao, L. Sun, Y. Pan, H. Wang and W. B. Zhang, *Bone*, 2018, **108**, 62–70.
- 81 Y. Huang, Y. Zheng, L. Jia and W. Li, *Stem Cells*, 2015, **33**, 3481–3492.
- 82 X. R. Jiang, N. Guo, X. Q. Li, H. Y. Yang, K. Wang, C. L. Zhang, G. S. Li and G. D. Li, *Eur. Rev. Med. Pharmacol. Sci.*, 2018, **22**, 2954–2965.
- 83 Y. Gao, F. Xiao, C. Wang, C. Wang, P. Cui, X. Zhang and X. Chen, *J. Cell. Biochem.*, 2018, **119**, 6986–6996.
- 84 W. Peng, W. Deng, J. Zhang, G. Pei, Q. Rong and S. Zhu, *Biochem. Biophys. Res. Commun.*, 2018, **503**, 815–821.
- 85 Q. He, S. Yang, X. Gu, M. Li, C. Wang and F. Wei, *Cell Death Dis.*, 2018, **9**, 455.
- 86 H. Li, Z. Zhang, Z. Chen and D. Zhang, *Biochem. Biophys. Res. Commun.*, 2015, **466**, 82–88.
- 87 W. Zhuang, X. Ge, S. Yang, M. Huang, W. Zhuang, P. Chen, X. Zhang, J. Fu, J. Qu and B. Li, *Stem Cells*, 2015, **33**, 1985–1997.
- 88 C. Jin, Y. Zheng, Y. Huang, Y. Liu, L. Jia and Y. Zhou, *Cell Biol. Int.*, 2017, **41**, 33–41.
- 89 Y. Yu, Y. Chen, X. Zhang, X. Lu, J. Hong, X. Guo and D. Zhou, *Cell Cycle*, 2018, **17**, 2374–2385.
- 90 Q. Wang, Q. Yang, G. Chen, Z. Du, M. Ren, A. Wang, H. Zhao, Z. Li, G. Zhang and Y. Song, *Sci. Rep.*, 2018, **8**, 9127.
- 91 Y. Huang, Y. Zheng, C. Jin, X. Li, L. Jia and W. Li, *Sci. Rep.*, 2016, **6**, 28897.
- 92 M. Li, X. Sun, H. Cai, Y. Sun, M. Plath, C. Li, X. Lan, C. Lei, F. Lin, Y. Bai and H. Chen, *Biochim. Biophys. Acta*, 2016, **1859**, 871–882.
- 93 W. Liu, C. Ma, B. Yang, C. Yin, B. Zhang and Y. Xiao, *Biochem. Biophys. Res. Commun.*, 2017, **493**, 1168–1175.
- 94 M. Li, Z. Xie, P. Wang, J. Li, W. Liu, S. Tang, Z. Liu, X. Wu, Y. Wu and H. Shen, *Cell Death Dis.*, 2018, **9**, 554.
- 95 F. F. Firmin, F. Oger, C. Gheeraert, J. Dubois-Chevalier, A. S. Vercoutter-Edouart, F. Alzaid, C. Mazuy, H. Dehondt, J. Alexandre, B. Derudas, Q. Dhalluin, M. Ploton, A. Berthier, E. Woitrain, T. Lefebvre, N. Venticlef, F. Pattou, B. Staels, J. Eeckhoutte and P. Lefebvre, *Sci. Rep.*, 2017, **7**, 14087.
- 96 R. Gernapudi, B. Wolfson, Y. Zhang, Y. Yao, P. Yang, H. Asahara and Q. Zhou, *Mol. Cell. Biol.*, 2016, **36**, 30–38.
- 97 N. Nuermaimaiti, J. Liu, X. Liang, Y. Jiao, D. Zhang, L. Liu, X. Meng and Y. Guan, *Biochem. Biophys. Res. Commun.*, 2018, **495**, 1878–1884.
- 98 Y. Huang, C. Jin, Y. Zheng, X. Li, S. Zhang, Y. Zhang, L. Jia and W. Li, *Sci. Rep.*, 2017, **7**, 8080.
- 99 L. Zhang, S. Chen, N. Bao, C. Yang, Y. Ti, L. Zhou and J. Zhao, *J. Mol. Histol.*, 2015, **46**, 467–473.
- 100 L. Zhang, C. Yang, S. Chen, G. Wang, B. Shi, X. Tao, L. Zhou and J. Zhao, *DNA Cell Biol.*, 2017, **36**, 136–142.
- 101 M. J. Barter, R. Gomez, S. Hyatt, K. Cheung, A. J. Skelton, Y. Xu, I. M. Clark and D. A. Young, *Development*, 2017, **144**, 4510–4521.



- 102 F. Ou, K. Su, J. Sun, W. Liao, Y. Yao, Y. Zheng and Z. Zhang, *Biochem. Biophys. Res. Commun.*, 2017, **487**, 457–463.
- 103 H.-l. Pang, Q.-q. Zhao, Y. Ma, Y.-l. Song, J. Min, J.-r. Lu, H. Li and D.-q. Zhao, *Stem Cells Int.*, 2019, **2019**, 11.
- 104 H. Wang, X. G. Ding, J. J. Yang, S. W. Li, H. Zheng, C. H. Gu, Z. K. Jia and L. Li, *Eur. J. Cell Biol.*, 2018, **97**, 180–189.
- 105 X. Sun, L. H. Luo, L. Feng and D. S. Li, *Life Sci.*, 2018, **208**, 246–252.
- 106 Y.-F. Tan, L. Tang, W.-X. OuYang, T. Jiang, H. Zhang and S.-J. Li, *Pathol., Res. Pract.*, 2019, **215**, 546–554.
- 107 J. Hou, H. Long, C. Zhou, S. Zheng, H. Wu, T. Guo, Q. Wu, T. Zhong and T. Wang, *Stem Cell Res. Ther.*, 2017, **8**, 4.
- 108 A. Farzi-Molan, S. Babashah, B. Bakhshinejad, A. Atashi and M. Fakhri Taha, *Cell Biol. Int.*, 2018, **42**, 940–948.
- 109 A.-M. Wu, W.-F. Ni, Z.-Y. Huang, Q.-L. Li, J.-B. Wu, H.-Z. Xu and L.-H. Yin, *J. Neurol. Sci.*, 2015, **351**, 160–167.

